



# THE COVAX FACILITY: INTERIM DISTRIBUTION FORECAST

– latest as of 3 February 2021

---

## INTRODUCTION

In line with initial guidance delivered [on 22 January](#), and building on the publication of the [2021 COVAX global and regional supply forecast](#), the COVAX Facility is pleased to share the following forecast on early availability of doses of the Pfizer-BioNTech vaccine and the AstraZeneca/Oxford vaccine to Facility participants, subject the caveats listed below.

This document contains information on indicative distribution of 240 million doses of the AstraZeneca/Oxford vaccine, licensed to Serum Institute of India (SII) – hereinafter “AZ/SII” and 96 million doses of the AstraZeneca/Oxford vaccine, under the advance purchase agreement between Gavi, the Vaccine Alliance and AstraZeneca – hereinafter “AZ”, for Q1 & Q2 2021.

It also contains an overview of exceptional first round allocation of 1.2 million doses of the WHO Emergency Use Listing (EUL)-approved Pfizer-BioNTech vaccine – hereinafter “Pfizer-BioNTech”, for Q1 2021.

It is important to note additional doses of both these products will be available to the COVAX Facility in 2021.

## ASTRAZENECA/OXFORD VACCINE: INDICATIVE DISTRIBUTION, Q1 & Q2 2021

### What is an “indicative distribution”?

This indicative distribution is intended to provide interim guidance to Facility participants – offering a planning scenario to enable preparations for the final allocation of the number of doses each participant will receive in the first rounds of vaccine distribution. It is therefore **non-binding and may be subject to change**, due to the caveats outlined below. Nevertheless, COVAX partners believe the publication of this information, which has now been shared with all economies participating in the COVAX Facility, marks an important first step in providing governments and public health leaders with the information they need to put in place practical steps for the provision of early doses and a successful national roll out of vaccines.

### Overview of the Process

It is important to note that WHO EUL has not yet been granted for the AstraZeneca vaccine<sup>1</sup>– although evaluation processes are [currently underway](#). Pending these final decisions, and based on current estimates of supply, the COVAX Facility has provided an indicative distribution for each Facility participant, covering Q1 and Q2 2021. The

---

<sup>1</sup> Three WHO Emergency Use Listing (EUL) evaluations are currently underway in relation to the AstraZeneca/Oxford vaccine: for doses manufactured by AstraZeneca, SK Bioscience, and Serum institute of India.



# COVAX Interim Distribution Forecast

As of 3 February 2021

final allocation of the AstraZeneca vaccine(s) will be undertaken following process and governance outlined to and agreed upon by all Facility participants, and will be subject to the validation of the Independent Allocation of Vaccine Group (IAVG).

It is important to underscore that the indicative distribution is based on current communication of estimated availability from manufacturers. In this regard, it is likely the distribution may need to be adjusted in light of circumstances that are difficult to anticipate and variables that are constantly evolving.

## Caveats

In order to understand the indicative distribution and future final allocation of this vaccine, it is important to consider the following:

- The actual allocation will only be announced once a product is granted the WHO EUL, and this indicative distribution information does not imply or pre-suppose that this vaccine will be granted WHO EUL;
- The indicative distribution takes into account current estimation of supply volumes.<sup>2</sup> The supply volume may vary due to manufacturing/and or operational constraints, and this will have an impact on the doses that will be allocated to countries;
- No doses will be allocated in the final allocation if a participant is deemed not ready (for AMC countries), which may cause variations in the quantities allocated to the other participants;
- The exact delivery after allocation will depend on the sequence of countries in the shipment plan, the time taken to place the purchase order, legal / regulatory obligations, as well as the supplier's lead time and related logistics;
- If during this period different products become available, this indicative distribution will need to be adjusted as different products may be allocated to a Facility participant and therefore the quantities indicated for the AstraZeneca/Oxford vaccine (both AZ/SII and AZ) may be altered.

## PFIZER-BIONTECH VACCINE: EXCEPTIONAL FIRST ROUND DISTRIBUTION, Q1 2021

### Overview of the Process

COVAX currently anticipates 1.2 million doses of the Pfizer-BioNTech vaccine will be available to the COVAX Facility in Q1 2021, subject to the completion of additional agreements, and will be complemented by the larger volumes of the AstraZeneca/Oxford vaccine available to the Facility during the same time period. Additional volumes of doses of the Pfizer-BioNTech vaccine will be available in the second quarter and beyond, per the signed advance purchase agreement between Gavi and Pfizer-BioNTech for up to 40 million doses.

As a result, an exceptional process of distribution was undertaken to ensure maximum public health benefit from the smaller volume of doses of the Pfizer-BioNTech vaccine anticipated to be available for Q1 delivery. All future allocation rounds will follow the standard Facility approach.

---

<sup>2</sup> 5% of H1 2021 doses were removed off the supply schedule from AZ/SII and AZ, subtracted from doses anticipated to be available in Q2 2021. This will be used for the Humanitarian and Contingency Buffers, if approved.

# COVAX Interim Distribution Forecast

As of 3 February 2021

On 6 January, COVAX offered the opportunity to all Facility participants who had not already opted-out of this product to express their interest in accessing an initial limited volume of the ultra-cold chain vaccine from Pfizer-BioNTech. As of the deadline of 18 January, the Facility had received 72 submissions (36 Advance Market Commitment participants and 36 self-financing participants). Six regional review committees (composed of staff from WHO, UNICEF, Gavi and members of Gavi's Independent Review Committee) undertook a technical assessment of the applications to make readiness recommendations.

Given the limited doses, the complexities related to rolling-out a vaccine requiring ultra-cold chain, and to ensure maximum public health impact, a decision was made to limit the number of countries for first deliveries of the Pfizer-BioNTech vaccine in order to enable successful distribution and delivery. Building on the principles of fairness, transparency, and equity for this exceptional early delivery allocation process, all Facility participants expressing interest in early deliveries of Pfizer-BioNTech and assessed as ready by the six regional review committees were divided by regional bloc – as per the six WHO regions – and by their Participant status (whether Self-Financing or AMC).

Based on the limited quantity of doses available, the list of participants was pared down via a WHO-led review process as follows, and based on information available as of 29 January:

- (1) Participant readiness: The majority of participants who applied were assessed to be ready.
- (2) Whether or not the participant had already initiated vaccination: As the intent of this initial roll-out was to allow participants to introduce a vaccine, it was stipulated that Participants that have initiated their COVID vaccination programme as of 29 January will not be included in the first exceptional allocation round for the Pfizer-BioNTech vaccine.
- (3) Self-financing participants' pricing preferences: If doses were within the price point indicated in their Facility application.
- (4) Assessment of risk of health care worker exposure: This is the key impact that this early exceptional distribution is aiming for, and as communicated to COVAX Participants on 6 January. As there is no direct measure of that exposure, a combination of indicators/data were used as a proxy, including mortality rates over the last 28 days.

## Caveats

Final supply of these doses is subject to:

- Negotiation and execution of additional agreements required;
- Confirmation of acceptance and enforceability of product handling requirements;
- Confirmation of AMC country readiness; and
- Confirmation of WHO EUL regulatory acceptance by participating countries.

# COVAX Interim Distribution Forecast

As of 3 February 2021

## OVERVIEW BY FACILITY PARTICIPANT

Total doses cover, on average, 3.3% of the total population of the 145 participants receiving doses from at least one manufacturer in the list detailed below. This is in line with the Facility target to reach at least 3% population coverage in all countries in the first half of the year, enough to protect the most vulnerable groups such as health care workers.

Participants that do not appear in the list below have either exercised their rights to opt-out, have not submitted vaccine requests, or have not yet been allocated doses.

### Notes of clarification

- For AZ/SII and AZ indicative distribution, delivery is estimated to begin as of late February, subject to WHO EUL, manufacturing supply capacity and completion of pre-requisites, as outlined in the related caveats section, above.
- For AZ/SII, indicative distribution doses specify contracted number of doses for Q1 + Q2 (first half – H1) supply, with 35-40% available in Q1 and 60-65% available in Q2.
- For AZ, range reflects H1 supply. Of the 170 million doses available via the advance purchase agreement between Gavi and AstraZeneca, 15% is anticipated to be available in Q1 and 42% available in Q2 – or 56%<sup>3</sup> overall in H1. Further supply is planned for the second half of the year.
- For Pfizer-BioNTech, doses are those anticipated for Q1 supply, pending successful satisfaction of caveats listed in the relevant section above.

WHO Region	Participant	SFP/AMC	# doses – AZ/SII (indicative distribution)	# doses – AZ/SKBio (indicative distribution)	# doses – Pfizer-BioNTech (exceptional allocation)
EMRO	Afghanistan	AMC	3,024,000	-	-
EURO	Albania	SFP	-	141,600	-
AFRO	Algeria	AMC	-	2,200,800	-
EURO	Andorra	SFP	-	26,400	-
AFRO	Angola	AMC	2,544,000	-	-
PAHO	Antigua and Barbuda	SFP	-	40,800	-
PAHO	Argentina	SFP	-	2,275,200	-
EURO	Armenia	SFP	-	146,400	-

<sup>3</sup> Actual numbers are 14.7% in Q1, 41.7% in Q2 totalling 56.4% in H1.

# COVAX Interim Distribution Forecast

As of 3 February 2021

EURO	Azerbaijan	SFP	-	506,400	-
PAHO	Bahamas	SFP	-	100,800	-
EMRO	Bahrain	SFP	-	100,800	-
SEARO	Bangladesh	AMC	12,792,000	-	-
PAHO	Barbados	SFP	-	100,800	-
PAHO	Belize	SFP	-	100,800	-
AFRO	Benin <sup>4</sup>	AMC	936,000	-	-
SEARO	Bhutan	AMC	108,000	-	5,850
PAHO	Bolivia	AMC	900,000	-	92,430
EURO	Bosnia and Herzegovina	SFP	-	153,600	23,400
AFRO	Botswana	SFP	-	117,600	-
PAHO	Brazil	SFP	-	10,672,800	-
WPRO	Brunei Darussalam	SFP	-	100,800	-
AFRO	Burkina Faso	AMC	1,620,000	-	-
AFRO	Cabo Verde	AMC	108,000	-	5,850
WPRO	Cambodia	AMC	1,296,000	-	-
AFRO	Cameroon	AMC	2,052,000	-	-
PAHO	Canada	SFP	-	1,903,200	-
AFRO	Central African Republic	AMC	372,000	-	-
AFRO	Chad	AMC	1,272,000	-	-
PAHO	Chile	SFP	-	957,600	-

<sup>4</sup> Participation pending final evaluation of vaccine request submitted to the COVAX Facility.

# COVAX Interim Distribution Forecast

As of 3 February 2021

PAHO	Colombia	SFP	-	2,553,600	117,000
AFRO	Comoros	AMC	108,000	-	-
AFRO	Congo, Dem. Rep.	AMC	6,948,000	-	-
AFRO	Congo, Rep.	AMC	420,000	-	-
PAHO	Costa Rica	SFP	-	254,400	-
AFRO	Cote d'Ivoire	AMC	2,040,000	-	-
EMRO	Djibouti	AMC	108,000	-	-
PAHO	Dominica	AMC	-	28,800	-
PAHO	Dominican Republic	SFP	-	542,400	-
PAHO	Ecuador	SFP	-	885,600	-
EMRO	Egypt, Arab Rep.	AMC	-	5,138,400	-
PAHO	El Salvador	AMC	-	324,000	51,480
AFRO	Eswatini	AMC	108,000	-	-
AFRO	Ethiopia	AMC	8,928,000	-	-
WPRO	Fiji	AMC	-	100,800	-
AFRO	Gambia, The	AMC	180,000	-	-
EURO	Georgia	SFP	-	184,800	29,250
AFRO	Ghana	AMC	2,412,000	-	-
PAHO	Grenada <sup>5</sup>	AMC	-	45,600	-
PAHO	Guatemala	SFP	-	847,200	-
AFRO	Guinea	AMC	1,020,000	-	-
AFRO	Guinea-Bissau	AMC	144,000	-	-

<sup>5</sup> See footnote 4, above.

# COVAX Interim Distribution Forecast

As of 3 February 2021

PAHO	Guyana	AMC	-	100,800	-
PAHO	Haiti <sup>6</sup>	AMC	876,000	-	-
PAHO	Honduras	AMC	-	496,800	-
SEARO	India	AMC	97,164,000	-	-
SEARO	Indonesia	AMC	-	13,708,800	-
EMRO	Iran	SFP	-	4,216,800	-
EMRO	Iraq	SFP	-	2,018,400	-
PAHO	Jamaica	SFP	-	146,400	-
EMRO	Jordan	SFP	-	511,200	-
AFRO	Kenya	AMC	4,176,000	-	-
WPRO	Kiribati	AMC	-	48,000	-
SEARO	Korea, Dem. People's Rep.	AMC	1,992,000	-	-
EURO	Kosovo	AMC	-	100,800	-
EURO	Kyrgyz Republic	AMC	504,000	-	-
WPRO	Lao PDR	AMC	564,000	-	-
EMRO	Lebanon	SFP	-	340,800	-
AFRO	Lesotho	AMC	156,000	-	-
AFRO	Liberia	AMC	384,000	-	-
EMRO	Libya	SFP	-	343,200	-
AFRO	Malawi	AMC	1,476,000	-	-
WPRO	Malaysia	SFP	-	1,624,800	-

<sup>6</sup> See footnote 4, above.

# COVAX Interim Distribution Forecast

As of 3 February 2021

SEARO	Maldives	AMC	108,000	-	5,850
AFRO	Mali	AMC	1,572,000	-	-
WPRO	Marshall Islands	AMC	-	24,000	-
AFRO	Mauritania	AMC	360,000	-	-
AFRO	Mauritius	SFP	-	100,800	-
PAHO	Mexico	SFP	-	6,472,800	-
WPRO	Micronesia, Fed. Sts.	AMC	-	48,000	-
EURO	Moldova	AMC	-	156,000	24,570
EURO	Monaco	SFP	-	7,200	-
WPRO	Mongolia	AMC	-	163,200	25,740
EURO	Montenegro	SFP	-	84,000	-
EMRO	Morocco	AMC	-	1,881,600	-
AFRO	Mozambique	AMC	2,424,000	-	-
SEARO	Myanmar	AMC	4,224,000	-	-
AFRO	Namibia	SFP	-	127,200	-
WPRO	Nauru	SFP	-	7,200	-
SEARO	Nepal	AMC	2,256,000	-	-
WPRO	New Zealand	SFP	-	249,600	-
PAHO	Nicaragua	AMC	504,000	-	-
AFRO	Niger	AMC	1,872,000	-	-
AFRO	Nigeria	AMC	16,008,000	-	-
EURO	North Macedonia	SFP	-	103,200	-
EMRO	Oman	SFP	-	254,400	-



# COVAX Interim Distribution Forecast

As of 3 February 2021

EMRO	Pakistan	AMC	17,160,000	-	-
PAHO	Panama	SFP	-	216,000	-
WPRO	Papua New Guinea	AMC	684,000	-	-
PAHO	Paraguay	SFP	-	357,600	-
PAHO	Peru	SFP	-	1,653,600	117,000
WPRO	Philippines	AMC	-	5,500,800	117,000
EMRO	Qatar	SFP	-	144,000	-
WPRO	Republic of Korea	SFP	-	2,596,800	117,000
AFRO	Rwanda	AMC	996,000	-	102,960
WPRO	Samoa	AMC	-	79,200	-
AFRO	Sao Tome and Principe	AMC	96,000	-	-
EMRO	Saudi Arabia	SFP	-	1,747,200	-
AFRO	Senegal	AMC	1,296,000	-	-
EURO	Serbia	SFP	-	345,600	-
AFRO	Sierra Leone	AMC	612,000	-	-
WPRO	Singapore	SFP	-	288,000	-
WPRO	Solomon Islands	AMC	108,000	-	-
EMRO	Somalia	AMC	1,224,000	-	-
AFRO	South Africa	SFP	-	2,976,000	117,000
AFRO	South Sudan	AMC	864,000	-	-
SEARO	Sri Lanka	AMC	1,692,000	-	-
PAHO	St. Kitts and Nevis	SFP	-	21,600	-

# COVAX Interim Distribution Forecast

As of 3 February 2021

PAHO	St. Lucia <sup>7</sup>	AMC	-	74,400	-
PAHO	St. Vincent and the Grenadines	AMC	-	45,600	-
EMRO	Sudan	AMC	3,396,000	-	-
PAHO	Suriname	SFP	-	79,200	-
EMRO	Syrian Arab Republic <sup>8</sup>	AMC	1,020,000	-	-
EURO	Tajikistan	AMC	732,000	-	-
SEARO	Timor-Leste	AMC	-	100,800	-
AFRO	Togo	AMC	636,000	-	-
WPRO	Tonga	AMC	-	43,200	-
PAHO	Trinidad and Tobago	SFP	-	100,800	-
EMRO	Tunisia	AMC	-	592,800	93,600
WPRO	Tuvalu	AMC	-	4,800	-
AFRO	Uganda	AMC	3,552,000	-	-
EURO	Ukraine	AMC	-	2,215,200	117,000
PAHO	Uruguay	SFP	-	172,800	-
EURO	Uzbekistan	AMC	2,640,000	-	-
WPRO	Vanuatu	AMC	-	100,800	-
PAHO	Venezuela	SFP	-	1,425,600	-
WPRO	Vietnam	AMC	-	4,886,400	-
EMRO	West Bank and Gaza	AMC	-	240,000	37,440
EMRO	Yemen, Rep.	AMC	2,316,000	-	-

<sup>7</sup> See footnote 4, above.

<sup>8</sup> Additional doses are allocated for distribution through UN partners given unique country context.

# COVAX Interim Distribution Forecast

As of 3 February 2021

AFRO	Zambia	AMC	1,428,000	-	-
AFRO	Zimbabwe <sup>9</sup>	AMC	1,152,000	-	-
Non-UN	Non-UN Member States	N/A	-	1,303,200	-

## NOTES

- Document was edited 3 February 2021 to add footnote 3, and clarification of related numbers.
- Document was edited 5 February 2021 to add footnote 9.

---

<sup>9</sup> Participation pending submission of vaccine request to the COVAX Facility.